Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (27)	2/20/2002 10:56:37 AM
From: keokalani'nui	Respond to of 130

AVANT Announces Preliminary Results of its Phase II Study of TP10 in Adults Undergoing Cardiac Surgery NEEDHAM, Mass.--(BW HealthWire)--Feb. 20, 2002--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - news) today announced that TP10, its lead complement inhibitor, failed to meet the primary endpoint in a double-blind, placebo-controlled Phase II study in adult patients undergoing high risk cardiac surgery. Announcing the results, Dr. Alistair Wheeler MD, Vice President, Medical Affairs of AVANT said, ``there were no clinically important differences between placebo and any of the four dose groups in the study. A total of 564 patients were randomized into the study to receive either one of four doses (1, 3, 5 or 10 mg/kg) of TP10, or placebo, as a thirty-minute intravenous infusion and were followed for 28 days post surgery. The primary efficacy endpoint of the study was the comparison of TP10 treated patients versus placebo who experienced either death, myocardial infarction, required prolonged intubation or prolonged intra-arterial balloon pump therapy. TP10 was well tolerated with no apparent differences in the safety profiles of the treatment groups.'' ``Obviously, we are extremely disappointed by the results of this study,'' said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. ``We are evaluating the future of the TP10 program but we no longer plan to advance TP10 in clinical development on our own nor do we intend to put anymore AVANT resources into this program. We will try to capture what value we can for the TP10 program,'' continued Dr. Ryan.